Clinical Trials Sponsored by Janssen Pharmaceuticals

Total 22232 results

Janssen Pharmaceutica

Completed

A Study to Assess the Severity of Psoriasis in Brazilians Participants With Chronic Plaque-type Psoriasis

Psoriasis | Plaque

Brazil
Janssen Pharmaceutica

Withdrawn

A Study of Safety and Effectiveness of Bendamustine Hydrochloride in Adult Filipino Patients With Chronic Lymphocytic Leukemia

Chronic Lymphocytic Leukemia
Janssen Pharmaceutica

Withdrawn

Post-marketing Surveillance Study on the Safety and Effectiveness of Abiraterone Acetate Among Adult Filipino Male Patients With Advanced Metastatic Castration Resistant Prostate Cancer

Prostate Neoplasms
Janssen Pharmaceutica

Withdrawn

A Study to Assess the Safety and Effectiveness of Golimumab in Filipino Patients With Rheumatoid Arthritis, Psoriatic Arthritis and Ankylosing Spondylitis

Rheumatoid Arthritis | Psoriatic Arthritis | Ankylosing Spondylitis
Janssen Pharmaceutica

Withdrawn

A Post Marketing Surveillance Study on the Safety and Effectiveness of Prucalopride in the Treatment of Chronic Constipation

Chronic Constipation

Philippines
Janssen Pharmaceutica

Completed

An Efficacy, Safety and Effects on Quality of Life of Tramadol/Paracetamol as Add-on Therapy in Chronic Osteoarthritis

Osteoarthritis

Philippines
Janssen Pharmaceutica

Completed

A Trial to Explore the Tolerability, Safety and Efficacy of Paliperidone Extended Release in Patients With Schizophrenia

Schizophrenia
Tracon Pharmaceuticals Inc.
Janssen Pharmaceutica N.V., Belgium

Completed

Phase 1/2A Study of TRC253, an Androgen Receptor Antagonist, in Metastatic Castration-resistant Prostate Cancer Patients

Metastatic Castrate-resistant Prostate Cancer | Adenocarcinoma, Prostate

United States
Janssen Pharmaceutica

Withdrawn

A Study to Assess the Safety and Effectiveness of Darunavir for Treating Human Immunodeficiency Virus-Type I (HIV-1) Infection in Filipino Patients

Human Immunodeficiency Virus-Type 1
Janssen Pharmaceutica

Withdrawn

A Safety and Effectiveness Study of Prolonged Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Chronic Non-Cancer Pain

Moderate to Severe Chronic Non-cancer Pain
Janssen Pharmaceutica

Terminated

Safety and Efficacy Study of Osmotic Release Oral System (OROS) Hydromorphone in Participants With Cancer Pain

Pain
Janssen Pharmaceutica

Completed

A Study of the Safety and Effectiveness of Doripenem in Filipino Patients With Nosocomial Pneumonia, Complicated Intra-Abdominal Infections and Complicated Urinary Tract Infections

Intraabdominal Infections | Pneumonia, Bacterial | Urinary Tract Infection | Nosocomial Infection

Philippines
Janssen Pharmaceutica

Completed

An Efficacy and Safety Study of Fentanyl Transdermal Patch in Filipino Participants With Osteoarthritis and Chronic Low Back Pain

Osteoarthritis | Low Back Pain

Philippines
Janssen Pharmaceutica

Completed

An Efficacy and Safety Study of Miconazole and Hydrocortisone Cream in the Treatment of Vulvar Candidiasis

Vulva; Candidiasis
Janssen Pharmaceutica

Withdrawn

A Study on the Safety and Effectiveness of Rilpivirine Hydrochloride (Edurant) Among Adult Filipino Patients With Human Immunodeficiency Virus Type-I Infection

Human Immunodeficiency Virus Type 1 (HIV-1) Infection
Janssen Pharmaceutica

Withdrawn

A Safety and Effectiveness Study of Immediate Release Tapentadol Hydrochloride Among Filipino Patients With Moderate to Severe Acute Non-Cancer Pain

Moderate to Severe Acute Non-Cancer Pain
Janssen Pharmaceutica

Completed

Safety, Efficacy and Tolerability Study of Paliperidone Extended-Release (ER) in Participants With Schizophrenia

Schizophrenia
Vertex Pharmaceuticals Incorporated
Janssen Pharmaceuticals

Terminated

An Open-Label Study of the Effect of Telaprevir in Combination With Peginterferon Alfa-2b and Ribavirin in Pediatric Subjects Infected With Hepatitis C Virus

Hepatitis C

United States, United Kingdom, Spain, Belgium, Italy, Germany
Janssen Pharmaceutical K.K.

Recruiting

A Study of JNJ-77242113 for the Treatment of Participants With Generalized Pustular Psoriasis or Erythrodermic Psoriasis

Generalized Pustular Psoriasis | Erythrodermic Psoriasis

Japan
Janssen Pharmaceutical K.K.

Recruiting

A Study of AAV5-hRKp.RPGR for the Treatment of Japanese Participants With X-linked Retinitis Pigmentosa

X-Linked Retinitis Pigmentosa

Japan
Janssen Pharmaceutical K.K.

Recruiting

A Study of Macitentan in Japanese Pediatric Participants With Pulmonary Arterial Hypertension

Pulmonary Arterial Hypertension

Japan
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of JNJ-64407564 in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Active, not recruiting

A Registry Study to Observe Clinical Outcomes of Participants With High-risk Metastatic Hormone-naïve Prostate Cancer in Japan

Prostatic Neoplasms

Japan
Janssen Pharmaceutical K.K.

Completed

An Observational Study of Japanese Participants With X-linked Retinitis Pigmentosa

X-Linked Retinitis Pigmentosa

Japan
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Crohns Disease

Japan
Janssen Pharmaceutical K.K.

Active, not recruiting

A Study of Guselkumab in Participants With Systemic Sclerosis

Scleroderma, Systemic

Japan
Janssen Pharmaceutical K.K.

Terminated

A Study of Adenovirus Serotype 26.Respiratory Syncytial Virus.Pre-Fusion F (Ad26.RSV.preF)-Based Vaccine for Prevention of Respiratory Syncytial Virus (RSV) Mediated- Lower Respiratory Tract Disease (LRTD) in Japanese Participants

Respiratory Syncytial Virus Prevention

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Ibrutinib in Combination With Rituximab, in Japanese Participants With Waldenstrom's Macroglobulinemia (WM)

Waldenstrom Macroglobulinemia

Japan
Janssen Pharmaceutical K.K.

Terminated

A Study of Amivantamab in Participants With Previously Treated Advanced or Metastatic Gastric or Esophageal Cancer

Stomach Neoplasms | Esophageal Neoplasms

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Subcutaneous Delivery of JNJ-54767414 (Daratumumab) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of JNJ-63723283, an Anti-Programmed Cell Death (PD)-1 Monoclonal Antibody, as Monotherapy or in Combination With Erdafitinib in Japanese Participants With Advanced Solid Cancers

Neoplasm

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Efficacy, Safety and Tolerability of Fixed Doses of Intranasal Esketamine in Japanese Participants With Treatment Resistant Depression

Depression

Japan
Janssen Pharmaceutical K.K.

Completed

An Exploratory Study of TMC207 in Japanese Participants With Pulmonary Multi-Drug Resistant Tuberculosis (MDR-TB)

Tuberculosis, Multidrug-Resistant

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Pharmacokinetics, and Efficacy of Combination Treatment of AL-335, Odalasvir, and Simeprevir in Japanese Participants With Chronic Hepatitis C Genotype 1 or 2 Virus Infection, With or Without Compensated Cirrhosis Who Are Direct Acting Antiviral Treatment-naive

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Withdrawn

A Study to Assess the Safety, Pharmacokinetics and Immunogenicity of CR8020 in Japanese Healthy Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics Following Subcutaneous Injection of JNJ-64304500 in Healthy Japanese and Caucasian Male Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of the Safety, Tolerability, Pharmacokinetics (What the Body Does to the Drug), and Pharmacodynamics (What the Drug Does to the Body) of CNTO 1959 Following a Single Subcutaneous (Under the Skin) Administration in Japanese Participants With Moderate to Severe Plaque Psoriasis

Psoriasis

Japan
Janssen Pharmaceutical K.K.

Completed

Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Relapsed or Refractory Mantle Cell Lymphoma

Lymphoma, Mantle-cell

Japan
Janssen Pharmaceutical K.K.

Completed

Pharmacokinetic Study of JNJ-56021927 When Taken Orally as Tablet Formulation in Healthy Male Japanese Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Evaluate the Pharmacokinetics of Rilpivirine/Tenofovir/Emtricitabine After a Single-Oral Administration in Healthy Japanese Adult Male Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of ALS-008176 in Healthy Japanese Adult Participants

Respiratory Syncytial Virus Infections

Japan
Janssen Pharmaceutical K.K.

Completed

A Comparative Study of JNS013 in Participants With Post-Tooth-Extraction Pain

Pain | Postoperative Pain

Japan
Janssen Pharmaceutical K.K.

Completed

A Study of Ustekinumab (STELARA®) in Adult Japanese Participants With Severe Atopic Dermatitis

Dermatitis, Atopic

Japan
Janssen Pharmaceutical K.K.

Completed

A Safety, Tolerability and Pharmacokinetics Study of JNJ-54861911 in Healthy Japanese Male Participants

Healthy

Japan
Janssen Pharmaceutical K.K.

Completed

An Efficacy and Safety Study of Ustekinumab (CNTO 1275) in Participants With Plaque Psoriasis

Psoriasis

Japan
Janssen Pharmaceutical K.K.

Terminated

A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

Multiple Myeloma

Japan
Janssen Pharmaceutical K.K.

Completed

A Study to Assess the Effectiveness, Safety, and Pharmacokinetics of TMC435 in Combination With Peginterferon Alfa-2a and Ribavirin in Hepatitis-C Infected Patients (DRAGON)

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Completed

A Phase III Study of TMC435 in Treatment-naive, Genotype 1, Hepatitis C-infected Patients

Hepatitis C, Chronic

Japan
Janssen Pharmaceutical K.K.

Completed

A Phase 2 Study of Tapentadol Extended-Release (JNS024ER) ) in Japanese Participants With Chronic Pain Due to Diabetic Neuropathic Pain or Postherpetic Neuralgia

Pain | Diabetic Neuropathies | Neuralgia | Postherpetic Neuralgia

Japan

3

Subscribe